Resverlogix Appoints Senior Vice President of Clinical Development
News Nov 04, 2014
Resverlogix Corp. has announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development.
Dr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications. This will include the company's Phase 2/3 trial of RVX-208 in patients with high-risk CVD with low HDL and diabetes mellitus.
"As we continue the development of RVX-208 for chronic diseases like CVD and diabetes mellitus, Michael brings highly relevant clinical development experience to our company," said Donald McCaffrey, president and chief executive officer of Resverlogix. "His expertise in vascular and cardiology product development will be beneficial as we prepare for the initiation of the Phase 2/3 trial of RVX-208 in patients with CVD and diabetes mellitus. We are set to begin enrolling patients in the first half of 2015 and plan additional trials to evaluate the drug in other conditions like Alzheimer's disease, peripheral artery disease, and chronic kidney disease."
Dr. Sweeney has an impressive career history, including 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of marketing of the Viagra® Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was a strategic pharmaceutical consultant for Impax Pharmaceuticals, Inc., a specialty pharmaceutical company with drug delivery and formulation technology, where he prepared a European marketing authorization application (MAA) for a product to treat neurologic disease.
Prior to Impax, Dr. Sweeney was Chief Medical Officer and vice president of research and development at Depomed, Inc., where he implemented the company's strategic plan for product development activities including opportunity assessment, clinical trials and interactions with the FDA.
Prior to Depomed, Dr. Sweeney was vice president of medical affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa® for patients with cardiovascular disease and chronic angina. Dr. Sweeney also spent time as a senior clinical pharmacologist and a medical advisor at Zeneca Group PLC (prior to the AstraZeneca merger).
Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He also is a fellow of the Royal College of Physicians of Edinburgh.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE